Galderma has launched its premium regenerative skincare brand Alastin across key Asia Pacific markets, including Japan, Singapore, South Korea, and Taiwan, expanding its presence in one of the fastest-growing regions for medical aesthetics and dermatological skincare.
The launches follow recent expansions in China and Australia and reflect Galderma’s continued investment in the JPAC region, where demand is increasing for science-based skincare solutions that support skin quality, procedure recovery, and long-term skin health.
Get the latest in Medical Aesthetics in our weekly ValuraNova Pulse. Sign up now.
Alastin’s portfolio includes peri-procedural and daily skincare products powered by its proprietary TriHex Technology®, which is designed to support the removal of damaged collagen and elastin while promoting the production of new, healthy skin proteins. The range is intended to complement aesthetic procedures such as energy-based treatments and injectables.
Nine Alastin products will be introduced across JPAC markets, including procedure-support products such as Skin Nectar and INhance, as well as daily treatment products targeting collagen renewal, hydration, pigmentation, and skin resilience.
Alan D. Widgerow, Chief Scientific Officer and Head of Innovation, Dermatological Skincare at Galderma, said:
“Alastin sets a new standard in regenerative skincare, and we’re excited to bring it to patients and healthcare professionals in the JPAC region, where demand for aesthetic procedures and peri-procedural care continues to grow.”
The expansion strengthens Galderma’s strategy of building an integrated aesthetics portfolio combining injectable treatments, regenerative skincare, and solutions focused on skin quality and longevity.
Read the full story here.
